AstraZeneca collaboration

AstraZeneca and Abbisko combine TAGRISSO with first-in-class oral PD-L1 drug for NSCLC

July 02, 2026 | 16:27

Abbisko Therapeutics (HKEX: 02256) and AstraZeneca (NYSE: AZN) entered a strategic collaboration to jointly advance Lumipodlin (ABSK043), a first-in-class oral PD-L1 inhibitor, in combination with TAGRISSO in non-small cell lung cancer clinical trials.

Tags

AstraZeneca collaboration

AstraZeneca and Abbisko combine TAGRISSO with first-in-class oral PD-L1 drug for NSCLC

Latest News

Gprnt and SGX Group upgrade ESGenome portal for climate reporting and transition planning

Dnotitia's STAR-KV cuts KV cache by up to 20x, earns ICML 2026 Spotlight selection

Ribo and Madrigal hit first clinical milestone on siRNA therapy programme for MASH

Vinamilk takes 5 prizes at World Dairy Innovation Awards, Southeast Asia's sole winner